Molecular mechanism in urothelial carcinoma with FGFR3 mutation.

被引：0
|
作者：
Liu, Huanhuan [1 ]
Zhang, Yanrui [1 ]
Lou, Feng [1 ]
Cao, Shanbo [1 ]
Wang, Huina [1 ]
机构：
[1] Acornmed Biotechnol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16548
引用
收藏
页码：E16548 / E16548
页数：1
相关论文
共 50 条
  • [41] Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis
    Rizzo, Alessandro
    Mollica, Veronica
    Santoni, Matteo
    Massari, Francesco
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 482 - 487
  • [42] Purine biosynthesis and related enzymes play the oncogenic function in FGFR3 mutant urothelial carcinoma
    Chang, Yu-Chan
    FASEB JOURNAL, 2022, 36
  • [43] FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations
    Lott, Sarah
    Wang, Mingsheng
    Zhang, Shaobo
    MacLennan, Gregory T.
    Lopez-Beltran, Antonio
    Montironi, Rodolfo
    Sung, Ming-Tse
    Tan, Puay-Hoon
    Cheng, Liang
    MODERN PATHOLOGY, 2009, 22 (05) : 627 - 632
  • [44] FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Jebar, AH
    Hurst, CD
    Tomlinson, DC
    Johnston, C
    Taylor, CF
    Knowles, MA
    ONCOGENE, 2005, 24 (33) : 5218 - 5225
  • [45] Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
    Cao, Jian-zhou
    Wu, Wei
    Pan, Jin-feng
    Wang, Hong-wei
    Jiang, Jun-hui
    Ma, Qi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
    Ibrahim, Tony
    Gizzi, Marco
    Bahleda, Ratislav
    Loriot, Yohann
    BLADDER CANCER, 2019, 5 (02) : 87 - 102
  • [47] FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
    Kacew, Alec
    Sweis, Randy F.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [48] cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
    Pal, S. K.
    Bajorin, D. F.
    Hoffman-Censits, J. H.
    Quinn, D. I.
    Petrylak, D. P.
    Galsky, M. D.
    Vaishampayan, U. N.
    De Giorgi, U.
    Gupta, S.
    Burris, H. A.
    Soifer, H. S.
    Li, G.
    Dambkowski, C. L.
    Moran, S.
    Wang, H.
    Daneshmand, S.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Erdafitinib in combination with BCLXL/BCL2 inhibitor induce apoptosis in urothelial carcinoma cells without FGFR mutation.
    Ohtsu, Akira
    Arai, Seiji
    Sawada, Tatsuhiro
    Suzuki, Kazuhiro
    CANCER RESEARCH, 2021, 81 (13)
  • [50] Analysis of acanthosis nigricans due to a fibroblast growth factor receptor 3 (FGFR3) Lys-650-Met mutation.
    Bellus, GA
    Whalen, E
    Norris, DA
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 615 - 615
12345